Correlation between Extracellular Matrix Metalloproteinase Inducer in Peripheral Blood and Serum MMPs in patients with Acute Coronary Syndrome

Wang, Wei

doi:10.14715/cmb/2022.68.11.16

Cited by 1 publication

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute coronary syndrome (ACS), the most common disease in cardiovascular, seriously threats human health and lives, including unstable angina (UA), acute myocardial infarction (AMI) and sudden cardiac death (SCD), and it is characterized by an imbalance in lipid metabolism, rupture of arterial plaque and inflammatory response of arterial wall [1][2][3]. Currently, the detailed molecular mechanisms regarding the ACS is still unclear.…”

Section: Introductionmentioning

confidence: 99%

Dynamic changes and clinical value of Sirt6 in acute coronary syndrome (ACS) patients

Gang Tian,

Chunxiao Zhang

2024

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study aimed to investigate the role of Sirt6 and inflammatory cytokines in blood samples of patients with ACS. This is a retrospective randomized controlled clinical trial, a total of 30 patients from our hospital are included and divided into following two groups: control group and experimental group, and experimental group consists of 15 patients with ACS and control group consists of 15 patients with non-acute coronary syndrome. Sirt6 protein is detected by western blotting and Sirt6 mRNA is detected by real-time PCR, then inflammatory cytokines such as IL-1β, IL-18, TnI, and CK-MB are measured by ELISA and cytokines NT-proBNP are monitored by immunofluorescence. Our outcomes show that Sirt6 protein and Sirt6 mRNA in experimental group are remarkably lower than those in control group, and IL-1β, IL-18, TnI, CK-MB, and NT-proBNP in the experimental group are remarkably higher than those in control group. We can conclude that Sirt6 can prevent or inhibit the development of ACS and IL-1β, IL-18, TnI, CK-MB, and NT-proBNP can accelerate the development of ACS.

show abstract

Section: Introductionmentioning

confidence: 99%